Today: Today, S&CO Inc. Maintains Stake in CVS Health Corporation (CVS)

Today, S&CO Inc. Maintains Stake in CVS Health Corporation (CVS)

S&CO Inc. held its position in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, Holdings Channel reports. The firm owned 7,285 shares of the pharmacy operator’s stock at the end of the third quarter. S&CO Inc.’s holdings in CVS Health Corporation were worth $648,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of CVS. Nordea Investment Management AB boosted its stake in CVS Health Corporation by 61.3% in the second quarter. Nordea Investment Management AB now owns 11,644,431 shares of the pharmacy operator’s stock valued at $1,114,838,000 after buying an additional 4,423,216 shares during the last quarter. Magellan Asset Management Ltd raised its position in shares of CVS Health Corporation by 1.6% in the second quarter. Magellan Asset Management Ltd now owns 10,300,505 shares of the pharmacy operator’s stock worth $986,170,000 after buying an additional 160,188 shares during the period. Dimensional Fund Advisors LP raised its position in shares of CVS Health Corporation by 2.3% in the second quarter. Dimensional Fund Advisors LP now owns 9,278,646 shares of the pharmacy operator’s stock worth $888,270,000 after buying an additional 205,585 shares during the period. Macquarie Group Ltd. raised its position in shares of CVS Health Corporation by 9.7% in the second quarter. Macquarie Group Ltd. now owns 7,707,523 shares of the pharmacy operator’s stock worth $737,919,000 after buying an additional 682,784 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of CVS Health Corporation by 0.8% in the second quarter. TIAA CREF Investment Management LLC now owns 6,819,880 shares of the pharmacy operator’s stock worth $652,935,000 after buying an additional 51,493 shares during the period. 81.78% of the stock is owned by institutional investors and hedge funds.

CVS Health Corporation (NYSE:CVS) traded up 0.53% on Friday, reaching $74.06. 3,529,190 shares of the company’s stock traded hands. The firm’s 50-day moving average is $81.80 and its 200 day moving average is $91.85. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $106.67. The stock has a market capitalization of $78.98 billion, a PE ratio of 15.87 and a beta of 0.88.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings data on Tuesday, November 8th. The pharmacy operator reported $1.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.57 by $0.07. The business earned $44.60 billion during the quarter, compared to the consensus estimate of $45.29 billion. CVS Health Corporation had a net margin of 2.96% and a return on equity of 17.18%. CVS Health Corporation’s quarterly revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.28 EPS. Analysts forecast that CVS Health Corporation will post $5.81 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, November 3rd. Shareholders of record on Monday, October 24th were issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 2.30%. The ex-dividend date of this dividend was Thursday, October 20th. CVS Health Corporation’s dividend payout ratio (DPR) is presently 36.40%.

A number of equities analysts have weighed in on CVS shares. Credit Suisse Group AG reiterated an “outperform” rating and issued a $110.00 price target (down previously from $115.00) on shares of CVS Health Corporation in a report on Tuesday, October 4th. Robert W. Baird decreased their price target on shares of CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating on the stock in a report on Monday, October 3rd. Leerink Swann reiterated an “outperform” rating and issued a $105.00 price target (down previously from $110.00) on shares of CVS Health Corporation in a report on Sunday, October 2nd. Vetr upgraded shares of CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $98.36 price target on the stock in a report on Monday, October 24th. Finally, Mizuho reiterated a “buy” rating and issued a $111.00 price target on shares of CVS Health Corporation in a report on Friday, September 30th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. CVS Health Corporation presently has a consensus rating of “Buy” and an average price target of $106.24.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment